Sanofi, Abbott Partner to Advance Diabetes Management

September 16, 2019

The companies aim to integrate glucose sensing with insulin delivery technologies to help change the way diabetes is managed.

On Sept. 16, 2019, Sanofi announced that it is partnering with Abbott to integrate glucose sensing and insulin delivery technologies that would help to further simplify the management of diabetes. The two companies will take an innovative approach to connected care by developing tools that combine Abbott’s FreeStyle Libre technology, a continuous glucose monitoring system that does not require a finger prick, with insulin dosing information for future smart pens, insulin titration apps, and cloud software.

The non-exclusive collaboration will initially enable data sharing, with the consent of the user, between Abbott’s FreeStyle Libre mobile app and cloud software and Sanofi’s connected insulin pens, apps, and cloud software that are currently in development. This data sharing will enable both people with diabetes and their doctors to make better informed treatment decisions around medication, nutrition, and lifestyle, the companies stated.

“For close to a century, Sanofi has been supporting those living with diabetes through our robust portfolio of medicines. This strategic relationship with Abbott is representative of the next evolution of our commitment for better diabetes care by incorporating digital tools into the daily life of people living with diabetes,” said Gustavo Pesquin, senior vice-president, Global Diabetes and Cardiovascular Franchise at Sanofi, in a company press release. “By partnering with Abbott, we are a step closer to realizing our connected ecosystem, which would help improve control and the quality of life decision cycle for patients through individualized glycemic management of diabetes.”

"As the global leader in continuous glucose monitoring, we see a significant opportunity to impact the health of millions of people living with diabetes by developing new tools and connectivity with Sanofi, a leader in the insulin space," said Jared Watkin, senior vice-president, Diabetes Care, Abbott, in the press release. "Diabetes can be overwhelming as it is an information-rich condition with various streams of data from multiple devices. Building a digital ecosystem around FreeStyle Libre simplifies the user experience by consolidating how people get their data-both through offering Abbott’s digital health tools and by working with other diabetes and technology leaders."

Sanofi is currently working to provide connected pens, apps, and cloud software that will be compatible with the FreeStyle Libre system and its compatible digital health tools. The two companies aim to bring this to people with diabetes within the next few years, pending local regulatory approvals.

Source: Sanofi